Endothelial Dysfunction and Inflammatory Markers of Vascular Disease

Author(s): Sevket Balta*

Journal Name: Current Vascular Pharmacology

Volume 19 , Issue 3 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Vascular diseases are the main reason for morbidity and mortality worldwide. As we know, the earlier phase of vascular diseases is endothelial dysfunction in humans, the endothelial tissues play an important role in inflammation, coagulation, and angiogenesis, via organizing ligand-receptor associations and the various mediators’ secretion. We can use many inflammatory non-invasive tests (flowmediated dilatation, epicedial fat thickness, carotid-intima media thickness, arterial stiffness and anklebrachial index) for assessing the endothelial function. In addition, many biomarkers (ischemia modified albumin, pentraxin-3, E-selectin, angiopoietin, endothelial cell specific molecule 1, asymmetrical dimethylarginine, von Willebrand factor, endothelial microparticles and endothelial progenitor cells) can be used to evaluate endothelial dysfunction. We have focused on the relationship between endothelial dysfunction and inflammatory markers of vascular disease in this review.

Keywords: Endothelial dysfunction, inflammatory markers, vascular disease.Endothelial dysfunction, inflammatory markers, vascular disease.

[1]
Theodorou K, Boon RA. Endothelial Cell Metabolism in Atherosclerosis. Front Cell Dev Biol 2018; 6: 82.
[http://dx.doi.org/10.3389/fcell.2018.00082] [PMID: 30131957]
[2]
Tabas I, García-Cardeña G, Owens GK. Recent insights into the cellular biology of atherosclerosis. J Cell Biol 2015; 209(1): 13-22.
[http://dx.doi.org/10.1083/jcb.201412052] [PMID: 25869663]
[3]
Tousoulis D, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. Heart 2006; 92(4): 441-4.
[PMID: 16159981]
[4]
Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Celik T, Iyisoy A. Endocan: A novel inflammatory indicator in cardiovascular disease? Atherosclerosis 2015; 243(1): 339-43.
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.09.030] [PMID: 26448266]
[5]
Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med 2008; 263(5): 517-27.
[http://dx.doi.org/10.1111/j.1365-2796.2008.01965.x] [PMID: 18410595]
[6]
Lekakis J, Abraham P, Balbarini A, et al. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Cardiovasc Prev Rehabil 2011; 18(6): 775-89.
[http://dx.doi.org/10.1177/1741826711398179] [PMID: 21450600]
[7]
Gimbrone MA Jr, García-Cardeña G. Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis. Cardiovasc Pathol 2013; 22(1): 9-15.
[http://dx.doi.org/10.1016/j.carpath.2012.06.006] [PMID: 22818581]
[8]
Topper JN, Gimbrone MA Jr. Blood flow and vascular gene expression: fluid shear stress as a modulator of endothelial phenotype. Mol Med Today 1999; 5(1): 40-6.
[http://dx.doi.org/10.1016/S1357-4310(98)01372-0] [PMID: 10088131]
[9]
Yong PJA, Koh CH, Shim WSN. Endothelial microparticles: missing link in endothelial dysfunction? Eur J Prev Cardiol 2013; 20(3): 496-512.
[http://dx.doi.org/10.1177/2047487312445001] [PMID: 22496273]
[10]
Boulanger CM. Endothelium. Arterioscler Thromb Vasc Biol 2016; 36(4): e26-31.
[http://dx.doi.org/10.1161/ATVBAHA.116.306940] [PMID: 27010027]
[11]
Raitakari OT, Celermajer DS. Flow-mediated dilatation. Br J Clin Pharmacol 2000; 50(5): 397-404.
[http://dx.doi.org/10.1046/j.1365-2125.2000.00277.x] [PMID: 11069434]
[12]
Corretti MC, Anderson TJ, Benjamin EJ, et al. International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39(2): 257-65.
[http://dx.doi.org/10.1016/S0735-1097(01)01746-6] [PMID: 11788217]
[13]
Kucuk A, Uslu AU, Arslan S, Balta S, Ozturk C, Uysal S, et al. Ischemia-Modified Albumin and Atherosclerosis in Patients with Familial Mediterranean Fever. Angiology 2015.
[PMID: 26238112]
[14]
Balta S, Aparci M, Ozturk C, Unlu M, Celik T. Carotid intima media thickness can predict coronary artery disease. Int J Cardiol 2015; 201: 331.
[http://dx.doi.org/10.1016/j.ijcard.2014.10.100] [PMID: 26301635]
[15]
Balta S, Balta I, Mikhailidis DP, et al. Bilirubin levels and their association with carotid intima media thickness and high-sensitivity C-reactive protein in patients with psoriasis vulgaris. Am J Clin Dermatol 2014; 15(2): 137-42.
[http://dx.doi.org/10.1007/s40257-014-0069-5] [PMID: 24696418]
[16]
Balta S, Demirkol S, Ay SA, Kurt O, Unlu M, Celik T. Nonalcoholic Fatty liver disease may be associated with coronary artery disease complexity. Angiology 2013; 64(8): 639-40.
[http://dx.doi.org/10.1177/0003319713483920] [PMID: 23564020]
[17]
Lundberg C, Hansen T, Ahlström H, Lind L, Wikström J, Johansson L. The relationship between carotid intima-media thickness and global atherosclerosis. Clin Physiol Funct Imaging 2014; 34(6): 457-62.
[http://dx.doi.org/10.1111/cpf.12116] [PMID: 24405735]
[18]
Charakida M, Masi S, Lüscher TF, Kastelein JJP, Deanfield JE. Assessment of atherosclerosis: the role of flow-mediated dilatation. Eur Heart J 2010; 31(23): 2854-61.
[http://dx.doi.org/10.1093/eurheartj/ehq340] [PMID: 20864485]
[19]
Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on Peripheral Circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis 2015; 241(2): 507-32.
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.05.007] [PMID: 26117398]
[20]
Iacobellis G, Willens HJ. Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr 2009; 22(12): 1311-9.
[http://dx.doi.org/10.1016/j.echo.2009.10.013] [PMID: 19944955]
[21]
Balta S, Demirkol S, Kurt Ö, Sarlak H, Akhan M. Epicardial adipose tissue measurement: inexpensive, easy accessible and rapid practical method. Anadolu Kardiyol Derg 2013; 13(6): 611.
[http://dx.doi.org/10.5152/akd.2013.207] [PMID: 24064089]
[22]
Katsiki N, Mikhailidis DP, Wierzbicki AS. Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol 2013; 28(4): 458-63.
[http://dx.doi.org/10.1097/HCO.0b013e3283605fba] [PMID: 23591557]
[23]
Balta I, Balta S, Ozturk C, Demirkol S, Demir M. Epicardial fat thickness in psoriasis patients. Dermatology (Basel) 2014; 228(2): 132-3.
[http://dx.doi.org/10.1159/000357403] [PMID: 24516065]
[24]
Sunbul M, Agirbasli M, Durmus E, et al. Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness. Atherosclerosis 2014; 237(2): 490-3.
[http://dx.doi.org/10.1016/j.atherosclerosis.2014.10.004] [PMID: 25463079]
[25]
Iacobellis G, Barbarini G, Letizia C, Barbaro G. Epicardial fat thickness and nonalcoholic fatty liver disease in obese subjects. Obesity (Silver Spring) 2014; 22(2): 332-6.
[http://dx.doi.org/10.1002/oby.20624] [PMID: 24115757]
[26]
Baragetti A, Pisano G, Bertelli C, et al. Subclinical atherosclerosis is associated with Epicardial Fat Thickness and hepatic steatosis in the general population. Nutr Metab Cardiovasc Dis 2016; 26(2): 141-53.
[http://dx.doi.org/10.1016/j.numecd.2015.10.013] [PMID: 26777475]
[27]
Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012; 33(10): 1190-200.
[http://dx.doi.org/10.1093/eurheartj/ehr453] [PMID: 22408036]
[28]
Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55(13): 1318-27.
[http://dx.doi.org/10.1016/j.jacc.2009.10.061] [PMID: 20338492]
[29]
Balta I, Balta S, Demirkol S, et al. Aortic arterial stiffness is a moderate predictor of cardiovascular disease in patients with psoriasis vulgaris. Angiology 2014; 65(1): 74-8.
[http://dx.doi.org/10.1177/0003319713485805] [PMID: 23636854]
[30]
Balta I, Balta S, Koryurek OMMOM, et al. Mean platelet volume is associated with aortic arterial stiffness in patients with Behçet’s disease without significant cardiovascular involvement. J Eur Acad Dermatol Venereol 2014; 28(10): 1388-93.
[http://dx.doi.org/10.1111/jdv.12297] [PMID: 24164056]
[31]
Çakar M, Balta Ş, Şarlak H, et al. Arterial stiffness and endothelial inflammation in prediabetes and newly diagnosed diabetes patients. Arch Endocrinol Metab 2015; 59(5): 407-13.
[http://dx.doi.org/10.1590/2359-3997000000061] [PMID: 26201008]
[32]
Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation [Internet 2003 Jun 10 [cited 2012 Aug 15]; 107(22): 2864-9.Available from.
[http://dx.doi.org/www.ncbi.nlm.nih.gov/pubmed/1279641410.1161/01.CIR.0000069826.36125.B4]
[33]
Balta S, Demirkol S, Demir M, Ozturk C, Aparcı M, Celik T. Ankle-brachial index in coronary artery disease. Clinics (São Paulo) 2014; 69(9): 653.
[http://dx.doi.org/10.6061/clinics/2014(09)13] [PMID: 25318099]
[34]
Papamichael CM, Lekakis JP, Stamatelopoulos KS, et al. Ankle-brachial index as a predictor of the extent of coronary atherosclerosis and cardiovascular events in patients with coronary artery disease. Am J Cardiol 2000; 86(6): 615-8.
[http://dx.doi.org/10.1016/S0002-9149(00)01038-9] [PMID: 10980210]
[35]
Zuwała-Jagiełło J, Warwas M, Pazgan-Simon M. Ischemia-modified albumin (IMA) is increased in patients with chronic hepatitis C infection and related to markers of oxidative stress and inflammation. Acta Biochim Pol 2012; 59(4): 661-7.
[http://dx.doi.org/10.18388/abp.2012_2107] [PMID: 23227456]
[36]
Uslu AU, Kucuk A, Balta S, Ozturk C, Arslan S, Tekin L, et al. The relation between ischemia modified albumin levels and carotid intima media thickness in patients with rheumatoid arthritis. Int J Rheum Dis 2016.
[PMID: 27028097]
[37]
Karaman M, Balta S, Seyit Ahmet AY, et al. The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension. Clin Exp Hypertens 2013; 35(7): 516-22.
[http://dx.doi.org/10.3109/10641963.2012.758734] [PMID: 23289969]
[38]
Celık T, Balta S, Karaman M, Ahmet Ay S, Demırkol S, Ozturk C, et al. Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: Comparative effects of amlodipine and valsartan. Blood Press 2014; 1: 6.
[PMID: 25390761]
[39]
Balta S, Mikhailidis DP, Demirkol S, et al. Endocan--a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology 2014; 65(9): 773-7.
[http://dx.doi.org/10.1177/0003319713513492] [PMID: 24402320]
[40]
Icli A, Cure E, Cure MC, Uslu AU, Balta S, Mikhailidis DP, et al. Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. Angiology 2015.
[PMID: 26614790]
[41]
Balta I, Balta S, Koryurek OM, et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol 2014; 70(2): 291-6.
[http://dx.doi.org/10.1016/j.jaad.2013.09.013] [PMID: 24176522]
[42]
Balta I, Balta S, Demirkol S, et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol 2013; 169(5): 1066-70.
[http://dx.doi.org/10.1111/bjd.12525] [PMID: 23889284]
[43]
Norata GD, Garlanda C, Catapano AL. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med 2010; 20(2): 35-40.
[http://dx.doi.org/10.1016/j.tcm.2010.03.005] [PMID: 20656213]
[44]
Carrizzo A, Lenzi P, Procaccini C, et al. Pentraxin 3 induces Vascular Endothelial Dysfunction Through a P-selectin/Matrix Metalloproteinase-1 Pathway. Circulation 2015; 131(17): 1495-505.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.114.014822] [PMID: 25747934]
[45]
Bonacina F, Baragetti A, Catapano AL, Norata GD. Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases. Mediators Inflamm 2013; 2013725102
[http://dx.doi.org/10.1155/2013/725102] [PMID: 23690668]
[46]
Fornai F, Carrizzo A, Forte M, et al. The inflammatory protein Pentraxin 3 in cardiovascular disease. Immun Ageing 2016; 13(1): 25.
[http://dx.doi.org/10.1186/s12979-016-0080-1] [PMID: 27559355]
[47]
Liu S, Qu X, Liu F, Wang C. Pentraxin 3 as a prognostic biomarker in patients with systemic inflammation or infection. Mediators Inflamm 2014; 2014421429
[http://dx.doi.org/10.1155/2014/421429] [PMID: 25530683]
[48]
Balta Ş, Çelik T, Aparcı M, Kurtoğlu E, Öztürk C. ADMA is a useful marker, but many confounding factors should be considered! Anatol J Cardiol 2015; 15(1): 81.
[http://dx.doi.org/10.5152/akd.2014.5894] [PMID: 25550257]
[49]
Kurtoglu E, Balta S, Sincer I, Altas Y, Atas H, Yilmaz M, et al. Comparision of Effects of Rosuvastatin Versus Atorvastatin Treatment on Plasma Levels of Asymmetric Dimethylarginine in Patients With Hyperlipidemia Having Coronary Artery Disease. Angiology 2013.
[PMID: 24163120]
[50]
Cakar M, Bulucu F, Karaman M, Ay SA, Kurt O, Balta S, et al. Asymmetric Dimethylarginine and Augmentation Index in Newly Diagnosed Patients with Hypertension. Angiology 2013.
[PMID: 24301421]
[51]
Mahmoud AM, Wilkinson FL, McCarthy EM, et al. Endothelial microparticles prevent lipid-induced endothelial damage via Akt/eNOS signaling and reduced oxidative stress. FASEB J 2017; 31(10): 4636-48.
[http://dx.doi.org/10.1096/fj.201601244RR] [PMID: 28687612]
[52]
Burger D, Turner M, Xiao F, Munkonda MN, Akbari S, Burns KD. High glucose increases the formation and pro-oxidative activity of endothelial microparticles. Diabetologia 2017; 60(9): 1791-800.
[http://dx.doi.org/10.1007/s00125-017-4331-2] [PMID: 28601907]
[53]
Hu L, Dai S-C, Luan X, Chen J, Cannavicci A. Dysfunction and Therapeutic Potential of Endothelial Progenitor Cells in Diabetes Mellitus. J Clin Med Res 2018; 10(10): 752-7.
[http://dx.doi.org/10.14740/jocmr3581w] [PMID: 30214646]
[54]
Fujisawa T, Wang K, Niu X-L, et al. Angiopoietin-1 promotes atherosclerosis by increasing the proportion of circulating Gr1+ monocytes. Cardiovasc Res 2017; 113(1): 81-9.
[http://dx.doi.org/10.1093/cvr/cvw223] [PMID: 28069704]
[55]
Alfieri A, Ong ACM, Kammerer RA, et al. Angiopoietin-1 regulates microvascular reactivity and protects the microcirculation during acute endothelial dysfunction: role of eNOS and VE-cadherin. Pharmacol Res 2014; 80: 43-51.
[http://dx.doi.org/10.1016/j.phrs.2013.12.008] [PMID: 24407281]
[56]
Bassyouni IH, Sharaf M, Wali IE, Mansour HM. Clinical significance of Angiopoietin-1 in Behcet’s disease patients with vascular involve-ment. Heart Vessels 2016; 31(6): 918-24.
[http://dx.doi.org/10.1007/s00380-015-0686-9] [PMID: 25964071]
[57]
Agostini S, Lionetti V. New insights into the non-hemostatic role of von Willebrand factor in endothelial protection. Can J Physiol Pharmacol 2017; 95(10): 1183-9.
[http://dx.doi.org/10.1139/cjpp-2017-0126] [PMID: 28715643]
[58]
Leitner GC, Schmetterer L, Kapiotis S, Jilma B. Effects of endothelin-1 and phenylephrine on plasma levels of von Willebrand factor and protein S. Thromb Res 2010; 125(1): e5-8.
[http://dx.doi.org/10.1016/j.thromres.2009.08.004] [PMID: 19729191]
[59]
Murdoch CE, Alom-Ruiz SP, Wang M, et al. Role of endothelial Nox2 NADPH oxidase in angiotensin II-induced hypertension and vasomotor dysfunction. Basic Res Cardiol 2011; 106(4): 527-38.
[http://dx.doi.org/10.1007/s00395-011-0179-7] [PMID: 21528437]
[60]
Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007; 100(2): 158-73.
[http://dx.doi.org/10.1161/01.RES.0000255691.76142.4a] [PMID: 17272818]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 3
Year: 2021
Published on: 21 April, 2020
Page: [243 - 249]
Pages: 7
DOI: 10.2174/1570161118666200421142542
Price: $65

Article Metrics

PDF: 47
HTML: 3